Tildrakizumab
- Generic Name
- Tildrakizumab
- Brand Names
- Ilumya, Ilumetri
- Drug Type
- Biotech
- CAS Number
- 1326244-10-3
- Unique Ingredient Identifier
- DEW6X41BEK
- Background
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter .
A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects .
- Indication
Moderate-severe plaque psoriasis , .
- Associated Conditions
- Moderate to Severe Plaque Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 55
- Registration Number
- NCT03718299
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Site 02, Grandville, Michigan, United States
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 1090
- Registration Number
- NCT01729754
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 772
- Registration Number
- NCT01722331
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.